Navigation Links
Bionovo Reports Third Quarter 2008 Financial Results
Date:11/3/2008

compensation and benefits 870,435 462,485

Current portion of lease obligation 793,242 706,710

Other current liabilities 467,088 949,200

Total current liabilities 3,115,031 2,716,631

Non-current portion of lease obligation 693,519 526,346

Commitments and contingencies

Shareholders' equity:

Preferred stock, $0.0001 par value;

10,000,000 shares authorized; none issued

and outstanding - -

Common stock, $0.0001 par value,

190,000,000 shares authorized; 76,363,101

and 76,343,101 shares issued and outstanding

as of September 30, 2008 and December 31,

2007, respectively 7,636 7,634

Additional paid-in capital 58,737,205 57,660,045

Accumulated other comprehensive income (53,450) 4,480

Accumulated deficit (35,963,783) (22,749,965)

Total shareholders' equity 22,727,608 34,922,194

Total liabilities and shareholders'

equity $26,536,158 $38,165,171

* The balance sheet at December 31, 2007 has been derived from the audited

financial statements at that date but does not include all of the

information and footnotes required by accounting principles generally

accepted in the United States for complete financial statements.


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bionovo to Present at A.G. Edwards 2nd Annual Emerging Growth Conference 2007
2. Bionovo Announces Proposed Public Offering of Common Stock
3. Bionovo to Present at the Biotechnology Industry Organization (BIO) Investor Forum
4. Bionovo Announces the Pricing of Public Offering of Shares of Common Stock
5. Bionovo Announces Third Quarter 2007 Financial Results
6. Bionovo to Present at Bank of Montreals 2007 Focus on Healthcare Conference
7. George Butler Joins Bionovos Board of Directors
8. Louis Drapeau Joins Bionovos Board of Directors
9. Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness
10. Bionovo to Present Recent Findings of BN107 and BN108, Its Anticancer Agents, at the American Association of Cancer Research
11. Bionovo Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Israel , July 25, 2014  Galmed Pharmaceuticals ... biopharmaceutical company focused on the development and commercialization of ... diseases and cholesterol gallstones, today announced financial results for ... Half 2014 Financial Summary: , Reported cash and ... compared with $137,000 at December 31, 2013.  , ...
(Date:7/24/2014)... New York, NY - July 24, 2014 -- Keryx ... results from the long-term, randomized, active control Phase 3 ... ferric iron-based phosphate binder, for the treatment of hyperphosphatemia ... The PERFECTED study (PhosphatE binding and iRon delivery with ... the Journal of the American Society of Nephrology ...
(Date:7/24/2014)... 24, 2014  Asterias Biotherapeutics, Inc. (OTCBB: ASTYV), ... of regenerative medicine, announced today that it will ... investors on Tuesday, July 29, 2014, at 4:30 ... include an overview of Asterias, business strategy and ... http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 minutes before ...
(Date:7/24/2014)... yet to materialise. Yet, scientists are making progress ... faster. One such approach relies on quantum dotsa ... an electric field. A new study demonstrates that ... dots (TQDs) with electrical impulses can help better ... TQDs be used as quantum information units, which ...
Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... Germany and MINNEAPOLIS, Minnesota, February 11, Bayer HealthCare ... Minneapolis, MN, (Nasdaq: POSS ), announced today ... pursuant to which,MEDRAD will acquire Possis Medical in ... or a total equity value of approximately US-Dollar ...
... Feb. 11 Replikins Ltd. announced that the,quantitative ... structure,predicts that the current H5N1 cycle is over. ... and high mortality characteristics,are expected to subside - ... or,another influenza virus strain begins., 140,000 virus ...
... Cryo-Cell,International, Inc. (OTC Bulletin Board Symbol: CCEL) (the ... family cord blood banks, today,announced results for fiscal ... ended November 30, 2007 were,approximately $17.5 million, up ... ended November 30, 2006. The Company reported a ...
Cached Biology Technology:Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 2Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 3Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 4Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 5Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 6FluForecast(R) Replikin Count(TM) Predicts That the H5N1 Cycle Which Began in 1996 Is Now Over 2Cryo-Cell International, Inc. Reports Results for Fiscal 2007 2Cryo-Cell International, Inc. Reports Results for Fiscal 2007 3Cryo-Cell International, Inc. Reports Results for Fiscal 2007 4Cryo-Cell International, Inc. Reports Results for Fiscal 2007 5Cryo-Cell International, Inc. Reports Results for Fiscal 2007 6
(Date:7/24/2014)... at Albert Einstein College of Medicine of ... J. Fox Foundation for Parkinson,s Research to translate a ... This drug discovery project will test chemical compounds on ... a drug that acts on an underlying cause of ... help many people manage their symptoms, we are eager ...
(Date:7/24/2014)... NJIT this week for an all-day public forum on ... Agency (EPA) to dredge toxic sediment from an eight-mile ... has called the plan, which proposes removing 4.3 million ... the riverbed, one of the largest cleanups in the ... disposed off-site. , "We need to ensure the future ...
(Date:7/24/2014)... researchers and patients have hoped that embryonic stem cells ... bodycould provide insight into numerous diseases perhaps even be ... by the inability to transfer research and tools from ... because human ESCs are "primed" and slightly less plastic ... Powell, and Haoyi Wang, who are scientists in the ...
Breaking Biology News(10 mins):Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3Experts Weigh the Pros and Cons of a $1.7 Billion EPA Cleanup Plan for the Passaic River at an NJIT 2Whitehead Institute researchers create 'naïve' pluripotent human embryonic stem cells 2
... Imagine a polka-dotted postage stamp that can sniff out poisonous ... reported in the Sept. 13 issue of the journal ... University of Illinois have developed an artificial nose for the ... fast and inexpensive and works by visualizing odors. ...
... The master gene that causes blood stem cells to ... identified by scientists, in a study published in Nature ... boost the body,s production of these frontline tumour-killing cells, creating ... ,knocked out, the gene in question, known as E4bp4, in ...
... a widespread and expensive social problem. Recent research ... interaction between genetic inheritance and environment for development ... common knowledge that childhood maltreatment often causes psychiatric ... (e.g. aggression or antisocial behaviour) later in life. ...
Cached Biology News:Opto-electronic nose sniffs out toxic gases 2Opto-electronic nose sniffs out toxic gases 3Master gene that switches on disease-fighting cells identified by scientists 2Master gene that switches on disease-fighting cells identified by scientists 3Are the monoamines involved in shaping conduct disorders? 2Are the monoamines involved in shaping conduct disorders? 3Are the monoamines involved in shaping conduct disorders? 4Are the monoamines involved in shaping conduct disorders? 5Are the monoamines involved in shaping conduct disorders? 6
Rabbit anti Xanthine Oxidase Xanthine Oxidase, Bovine Buttermilk...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (E6027) or contact customer s...
... large numbers of samples may be carried out ... operator attention. System control and data processing ... 4900. The elegant, powerful and very easy ... Windows 98 and 2000., The supplied detector is ...
Narrow-mouth has heavy-duty rim. Approximate graduations are in durable white enamel. Extra large marking space. capacity 125 mL Special grade: student grade...
Biology Products: